The trajectory of companies tied to Viagra's legacy presents a challenging investment picture . While the initial success generated substantial returns , generic alternatives have significantly diminished sales . Investing in related pharmaceutical firms now requires a discerning assessment of proprietary protection , evolving patient shifts , and